1. Zaboli Mahdiabadi M, Karami C, Saber E, Kamali M, Orandi A, Dadashi A, et al. Effectiveness of molnupiravir in the treatment of patients with COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2023;33(12):857-67. [
DOI:10.61186/umj.33.12.857]
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727-33. [
DOI:10.1056/NEJMoa2001017] [
PMID] [
]
3. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. JAMA Intern Med 2020;180(11):1447-52. [
DOI:10.1001/jamainternmed.2020.3862] [
PMID] [
]
4. Amani B, Akbarzadeh A, Amani B, Shabestan R, Khorramnia S, Navidi Z, et al. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis. J Med Virol 2023;95(6):e28889. [
DOI:10.1002/jmv.28889] [
PMID]
5. Amani B, Zareei S, Amani B, Zareei M, Zareei N, Shabestan R, et al. Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence. Immun Inflamm Dis 2022;10(6):e628. [
DOI:10.1002/iid3.628] [
PMID] [
]
6. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19(3):141-54. [
DOI:10.1038/s41579-020-00459-7] [
PMID] [
]
7. Ahorsu DK, Lin CY. The effect of COVID-19 vaccine acceptance, intention, and/or hesitancy and its association with our health and/or important areas of functioning. Vaccines 2023;11(2):368. [
DOI:10.3390/vaccines11020368] [
PMID] [
]
8. Wu N, Joyal-Desmarais K, Ribeiro PA, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med 2023;11(5):439-52. [
DOI:10.1016/S2213-2600(23)00015-2] [
PMID]
9. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022;22(9):1293-302. [
DOI:10.1016/S1473-3099(22)00320-6] [
PMID]
10. Taylor PC, Adams AC, Hufford MM, De La Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 2021;21(6):382-93. [
DOI:10.1038/s41577-021-00542-x] [
PMID] [
]
11. Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. Jama 2020;324(2):131-2. [
DOI:10.1001/jama.2020.10245] [
PMID]
12. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Eng J Med 2021;385(21):1941-50. [
DOI:10.1056/NEJMoa2107934] [
PMID]
13. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med 2021;385(15):1382-92. [
DOI:10.1056/NEJMoa2102685] [
PMID] [
]
14. O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan K-C, Sarkar N, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med 2021;385(13):1184-95. [
DOI:10.1056/NEJMoa2109682] [
PMID] [
]
15. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020;369(6506):1010-4. [
DOI:10.1126/science.abd0827] [
PMID] [
]
16. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021;384(3):238-51. [
DOI:10.1056/NEJMoa2035002] [
PMID] [
]
17. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021;384(3):229-37. [
DOI:10.1056/NEJMoa2029849] [
PMID] [
]
18. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25(9):603-5. [
DOI:10.1007/s10654-010-9491-z] [
PMID]
19. Khorramnia S, Jafari A, Farahbakhsh F, Aliniaghara E, Amani B, Amani B, et al. Estimation of mortality in the intensive care units in iran: A systematic review and meta-analysis. Nurs Midwif J 2019;17(8):634-45. [
Google Scholar]
20. Al-Obaidi MM, Gungor AB, Nematollahi S, Zangeneh TT, Bedrick EJ, Johnson KM, et al., editors. Effectiveness of casirivimab-imdevimab monoclonal antibody treatment among high-risk patients With severe acute respiratory syndrome coronavirus 2 B. 1.617. 2 (Delta Variant) infection. Open forum infectious diseases; 2022: Oxford University Press. [
DOI:10.1093/ofid/ofac186] [
PMID] [
]
21. Amano N, Iwata K, Iwata S. Clinical effectiveness of REGN-COV2 in patients with COVID-19 in Japan: a retrospective cohort study with a Bayesian inference. Infect Chemother 2021;53(4):767. [
DOI:10.3947/ic.2021.0125] [
PMID] [
]
22. Faraone A, Fabbrizzi F, Picchioni T, Lovicu E, Tofani L, Scocchera G, et al. REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experience, 05 May 2022, PREPRINT (Version 1) available at Research Square. [
DOI:10.21203/rs.3.rs-1170976/v1]
23. Hussein M, Wei W, Mastey V, Sanchez RJ, Wang D, Murdock DJ, et al. Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database. BMJ Open 2022;12(12):e064953. [
DOI:10.1136/bmjopen-2022-064953] [
PMID] [
]
24. Jalbert JJ, Hussein M, Mastey V, Sanchez RJ, Wang D, Murdock D, et al. Effectiveness of subcutaneous casirivimab and imdevimab in ambulatory patients with COVID-19. Infect Dis Ther 2022;11(6):2125-39. [
DOI:10.1007/s40121-022-00691-z] [
PMID] [
]
25. Joy AP, Augustine AT, Karattuthodi MS, Parambil JC, Chandrasekher D, Danisha P, et al. The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India. Clin Epidemiol Glob Health 2022;14:100967. [
DOI:10.1016/j.cegh.2022.100967] [
PMID] [
]
26. McCreary EK, Bariola JR, Wadas RJ, Shovel JA, Wisniewski MK, Adam M, et al. Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults with COVID-19. JAMA Network Open 2022;5(4):e226920-e. [
DOI:10.1001/jamanetworkopen.2022.6920] [
PMID] [
]
27. Miyashita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, Ishiura Y. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant. J Infect Chemother 2022;28(9):1344-6. [
DOI:10.1016/j.jiac.2022.05.012] [
PMID] [
]
28. Osugi Y, Iwata H, Imai Y, Kobayashi D, Hirashima R. Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan. Cureus 2022;14(2). [
DOI:10.7759/cureus.21882] [
PMID] [
]
29. Razonable RR, Pawlowski C, O'Horo JC, Arndt LL, Arndt R, Bierle DM, et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinMed 2021;40. [
DOI:10.1016/j.eclinm.2021.101102] [
PMID] [
]
30. Rhudy C, Bochenek S, Thomas J, St. James G, Zeltner M, Platt T. Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study. Am J Health Syst Pharm 2023;80(3):130-6. [
DOI:10.1093/ajhp/zxac305] [
PMID] [
]
31. Shopen N, Dekel M, Mizrahi M, Zandberg E, Talmud D, Cohen N. Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection. Eur J Intern Med 2022;100:137-9. [
DOI:10.1016/j.ejim.2022.03.001] [
PMID] [
]
32. Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, et al. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. Int J Med Sci 2022;19(5):834. [
DOI:10.7150/ijms.71132] [
PMID] [
]
33. Wei W, Murdock D, Jalbert JJ, Mastey V, Sanchez RJ, Hirshberg B, et al. Real-world effectiveness of Casirivimab and Imdevimab in patients with COVID-19 in the ambulatory setting: an analysis of two large US national claims databases. medRxiv 2022:2022.02. 28.22270796. [
DOI:10.1101/2022.02.28.22270796]
34. Gao M, Ao G, Hao X, Xie B. Casirivimab-Imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis. J Infect 2023. [
DOI:10.1016/j.jinf.2023.04.019] [
PMID] [
]
35. Deng J, Heybati K, Ramaraju HB, Zhou F, Rayner D, Heybati S. Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis. Infect 2023;51(1):21-35. [
DOI:10.1007/s15010-022-01825-8] [
PMID] [
]
36. Nathan R, Shawa I, De La Torre I, Pustizzi JM, Haustrup N, Patel DR, et al. A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2. Infect Dis Ther 2021;10(4):1933-47. [
DOI:10.1007/s40121-021-00515-6] [
PMID] [
]
37. McConnell D, Harte M, Walsh C, Murphy D, Nichol A, Barry M, et al. Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis. Sci Rep 2022;12(1):17561. [
DOI:10.1038/s41598-022-22431-6] [
PMID] [
]
38. Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: a systematic review and meta‐analysis of randomized controlled trials. J Med Virol 2022;94(5):2222-9. [
DOI:10.1002/jmv.27623] [
PMID] [
]
39. Yang M, Li A, Wang Y, Tran C, Zhao S, Ao G. Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: a meta-analysis. J Infect 2022;85(4):436-80. [
DOI:10.1016/j.jinf.2022.06.027] [
]
40. Khorramnia S, Jalili M, Salajegheh M, Mansouri M. Efficacy of bamlanivimab compared to standard care in treatment of the patients with COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2023;34(8):461-70. [
Google Scholar]
41. Tai Y-L, Lee M-D, Chi H, Chiu N-C, Lei W-T, Weng S-L, et al. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis. PeerJ 2023;11:e15344. [
DOI:10.7717/peerj.15344] [
PMID] [
]
42. Kow CS, Ramachandram DS, Hasan SS. The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Immunopharmacol Immunotoxicol 2022;44(1):28-34. [
DOI:10.1080/08923973.2021.1993894] [
PMID] [
]
43. Siemieniuk RA, Bartoszko JJ, Martinez JPD, Kum E, Qasim A, Zeraatkar D, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. Br Med J 2021;374. [
Google Scholar]
44. Zaboli Mahdiabadi M, Abbasi Dolatabadi Z, Nemati Dopolani F, Razavinasab SA, Ivanbagha R, Zeid Abadinejad MR, et al. Clinical effectiveness of regdanvimab in the treatment of patients with COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2023;33(11):786-95. [
DOI:10.52547/umj.33.11.786]
45. Bown M, Sutton A. Quality control in systematic reviews and meta-analyses. Eur J Vasc Endovasc Surg 2010;40(5):669-77. [
DOI:10.1016/j.ejvs.2010.07.011] [
PMID]
46. Alhumaid S, Al Mutair A, Alali J, Al Dossary N, Albattat SH, Al HajjiMohammed SM, et al. Efficacy and safety of tixagevimab/cilgavimab to prevent COVID-19 (pre-exposure prophylaxis): A systematic review and meta-analysis. Diseases 2022;10(4):118. [
DOI:10.3390/diseases10040118] [
PMID] [
]
47. Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev 2021(9). [
DOI:10.1002/14651858.CD013825.pub2] [
PMID] [
]
48. Amani B, Amani B. Efficacy and safety of sotrovimab in patients with COVID‐19: A rapid review and meta‐analysis. Rev Med Virol 2022;32(6):e2402. [
DOI:10.1002/rmv.2402] [
PMID] [
]
49. Hernandez AV, Piscoya A, Pasupuleti V, Phan MT, Julakanti S, Khen P, et al. Beneficial and harmful effects of monoclonal antibodies for the treatment and prophylaxis of COVID-19: a systematic review and meta-analysis of randomized controlled trials. Am J Med 2022. [
DOI:10.1016/j.amjmed.2022.06.019] [
PMID] [
]